DermTech, Inc. (DMTK): Price and Financial Metrics
GET POWR RATINGS... FREE!
DMTK POWR Grades
- Value is the dimension where DMTK ranks best; there it ranks ahead of 40.87% of US stocks.
- DMTK's strongest trending metric is Sentiment; it's been moving up over the last 179 days.
- DMTK ranks lowest in Momentum; there it ranks in the 1st percentile.
DMTK Stock Summary
- DMTK's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 11.69% of US stocks.
- With a year-over-year growth in debt of 186.48%, DERMTECH INC's debt growth rate surpasses 92.5% of about US stocks.
- In terms of volatility of its share price, DMTK is more volatile than 93.81% of stocks we're observing.
- Stocks that are quantitatively similar to DMTK, based on their financial statements, market capitalization, and price volatility, are WKME, USER, BMRA, AUPH, and ADN.
- DMTK's SEC filings can be seen here. And to visit DERMTECH INC's official web site, go to www.dermtech.com.
DMTK Valuation Summary
- DMTK's price/earnings ratio is -0.9; this is 104.03% lower than that of the median Healthcare stock.
- DMTK's price/earnings ratio has moved NA NA over the prior 65 months.
Below are key valuation metrics over time for DMTK.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DMTK | 2022-11-01 | 6.9 | 0.5 | -0.9 | 0 |
| DMTK | 2022-10-31 | 6.8 | 0.5 | -0.9 | 0 |
| DMTK | 2022-10-28 | 7.0 | 0.6 | -0.9 | 0 |
| DMTK | 2022-10-27 | 6.7 | 0.5 | -0.9 | 0 |
| DMTK | 2022-10-26 | 7.0 | 0.6 | -0.9 | 0 |
| DMTK | 2022-10-25 | 6.8 | 0.5 | -0.9 | 0 |
DMTK's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- DMTK has a Quality Grade of F, ranking ahead of 1.78% of graded US stocks.
- DMTK's asset turnover comes in at 0.055 -- ranking 76th of 81 Healthcare stocks.
- LFMD, AHCO, and RHE are the stocks whose asset turnover ratios are most correlated with DMTK.
The table below shows DMTK's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.055 | 0.128 | -1.299 |
| 2021-03-31 | 0.060 | 0.010 | -1.492 |
| 2020-12-31 | 0.089 | -0.016 | -1.875 |
| 2020-09-30 | 0.101 | -0.020 | -3.873 |
| 2020-06-30 | 0.102 | -0.017 | 12.100 |
| 2020-03-31 | 0.117 | 0.141 | -20.696 |
DMTK Price Target
For more insight on analysts targets of DMTK, see our DMTK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $62.00 | Average Broker Recommendation | 1.25 (Strong Buy) |
DMTK Stock Price Chart Interactive Chart >
DMTK Price/Volume Stats
| Current price | $2.41 | 52-week high | $20.59 |
| Prev. close | $2.39 | 52-week low | $1.66 |
| Day low | $2.31 | Volume | 218,500 |
| Day high | $2.43 | Avg. volume | 722,492 |
| 50-day MA | $3.27 | Dividend yield | N/A |
| 200-day MA | $7.40 | Market Cap | 72.82M |
DermTech, Inc. (DMTK) Company Bio
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Latest DMTK News From Around the Web
Below are the latest news stories about DERMTECH INC that investors may wish to consider to help them evaluate DMTK as an investment opportunity.
DermTech and Sonora Quest Laboratories Expand Access to Innovative Melanoma Detection TestLA JOLLA, Calif. & PHOENIX, November 15, 2022--DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today an agreement with Sonora Quest Laboratories (Sonora Quest), Arizona’s leading diagnostic laboratory, to expand access to enhanced melanoma detection. As a result of the agreement, Sonora Quest will be the exclusive laboratory in Arizona to offer the DermTech Melanoma Test to its vast network |
Stephens Sticks to Its Buy Rating for DermTech (DMTK)In a report released today, Mason Carrico from Stephens maintained a Buy rating on DermTech (DMTK - Research Report), with a price target of $5.00. The company's shares opened today at $1.85.According to TipRanks, Carrico is an analyst with an average return of -27.0% and a 16.67% success rate. Carrico covers the Healthcare sector, focusing on stocks such as Guardant Health, Myriad Genetics, and DermTech.DermTech has an analyst consensus of Strong Buy, with a price target consensus of $9.60, implying a 418.92% upside from current levels. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $6.00 price target. |
DermTech Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagDermTech ( NASDAQ:DMTK ) Third Quarter 2022 Results Key Financial Results Revenue: US$3.57m (up 18% from 3Q 2021). Net... |
DermTech, Inc. (NASDAQ:DMTK) Analysts Are Cutting Their Estimates: Here's What You Need To KnowOne of the biggest stories of last week was how DermTech, Inc. ( NASDAQ:DMTK ) shares plunged 50% in the week since its... |
DermTech, Inc. (DMTK) Reports Q3 Loss, Misses Revenue EstimatesDermTech, Inc. (DMTK) delivered earnings and revenue surprises of 3.03% and 26.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
DMTK Price Returns
| 1-mo | -23.73% |
| 3-mo | -58.59% |
| 6-mo | N/A |
| 1-year | -87.77% |
| 3-year | -69.95% |
| 5-year | N/A |
| YTD | -84.75% |
| 2021 | -51.29% |
| 2020 | 161.61% |
| 2019 | -39.28% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...